A busy Fall “leaves” little to no downtime for EpicentRx
What summer slowdown?
EpicentRx kicked off the Fall season in high gear with continuing preparations for the start of a large Phase 2b follow on study called KEVLARx with nibrozetone (RRx-001) in first line head and neck cancer. Positive data from KEVLARx will position the company well for an exit or an approval in severe oral mucositis.
At the same time, the Phase 3 clinical trial, REPLATINUM, with nibrozetone (RRx-001) plus a platinum doublet in third-line or beyond small cell lung cancer (SCLC) continues apace and top line results from it are expected in 2025.
In addition, EpicentRx submitted its second Phase 2 trial called HAI MAINTENANCE with AdAPT-001, the adenovirus that carries a TGF-β trap, in liver predominant colorectal cancer where AdAPT-001 is given systemically through the hepatic artery.
Other highlights from this Fall included the unofficial kickoff of a collaboration with Drs. Erin Greaves and Andrew Horne at the Universities of Warwick and Edinburgh in England, respectively, to evaluate nibrozetone (RRx-001) as a treatment for endometriosis, a painful gynecological condition that afflicts over 190 million women worldwide.
Also noteworthy and mentionable is a Department of Defense (DoD) grant that EpicentRx submitted with Dr. Richard Gordon from the Queensland University of Technology (QUT) to study nibrozetone (RRx-001) as a medical countermeasure against toxic military exposures.
Speaking of Dr. Gordon and QUT, Scott Caroen and Bryan Oronsky from EpicentRx presented with him to wide acclaim on the discovery and development of nibrozetone (RRx-001) as an anti-neurodegenerative agent at the OneTRI Conference in Brisbane, Australia.
Finally, EpicentRx attended the American Society for Radiation Oncology (ASTRO) annual meeting in San Diego, CA where it presented results from the PREVLAR Phase 2a trial. In PREVLAR, the addition of nibrozetone (RRx-001) to chemotherapy and radiation dramatically reduced the incidences of several toxicities including oral mucositis, dysphagia, anorexia, and skin injury.
So, as always, lots to update and discuss including more to come in November. Please check out our blog, our LinkedIn page, our press releases, our hopefully entertaining Twitter feed, and several new peer-reviewed publications including International Journal of Radiation Oncology, Biology, Physics and Future Oncology.
Thank you for taking the time read,
The EpicentRx Team